{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:58:51Z","timestamp":1791082731263,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270626"],"award-info":[{"award-number":["82270626"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870417"],"award-info":[{"award-number":["81870417"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070605"],"award-info":[{"award-number":["82070605"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2022CR63"],"award-info":[{"award-number":["2022CR63"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","award":["2025SF052"],"award-info":[{"award-number":["2025SF052"]}],"id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016079","name":"Science and Technology Department of Xinjiang Uygur Autonomous Region","doi-asserted-by":"publisher","award":["2020A03004-3"],"award-info":[{"award-number":["2020A03004-3"]}],"id":[{"id":"10.13039\/100016079","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing postdoctoral research activities innovation research and development fund","award":["2024-zz-102"],"award-info":[{"award-number":["2024-zz-102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) is a global disease that can induce severe conditions such as cirrhosis and liver cancer, posing a serious threat to human health. The low functional cure rate of existing antiviral treatment drugs is primarily due to the dysfunctional immune response in CHB patients and the difficulty in clearing intrahepatic cccDNA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This article reviews the latest progress in the research on therapeutic vaccines for CHB, to analyze and discuss the potential impact of current achievements and to outline the prospects for future research, exploring therapeutic strategies for the functional cure of CHB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Therapeutic vaccines are anticipated to activate specific immune responses in CHB patients, break the mechanisms of immune tolerance, and exhibit significant potential in maintaining long-term immune activity. Several therapeutic vaccines have already demonstrated promising therapeutic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic vaccines are of great significance in the field of CHB treatment. Current research achievements provide strong support for their application, while combined therapy offers new ideas and hope for future treatment directions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12072-025-10907-2","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T12:19:32Z","timestamp":1758975572000},"page":"1320-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Do the therapeutic vaccines hold hope for the treatment of hepatitis B?"],"prefix":"10.1007","volume":"19","author":[{"given":"Qiujing","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghuan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8577-0527","authenticated-orcid":false,"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0317-7536","authenticated-orcid":false,"given":"Guiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,27]]},"reference":[{"key":"10907_CR1","first-page":"2024","volume-title":"monitoring health for the SDGs","author":"World health statistics","year":"2024","unstructured":"World health statistics. monitoring health for the SDGs. Sustainable Development Goals. Geneva: World Health Organization; 2024. p. 2024"},{"key":"10907_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10823-5","author":"J Chen","year":"2025","unstructured":"Chen J, Ji D, Jia J, et al. Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis. Hepatol Int. 2025. https:\/\/doi.org\/10.1007\/s12072-025-10823-5","journal-title":"Hepatol Int"},{"issue":"6","key":"10907_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100361","volume":"3","author":"H Ma","year":"2021","unstructured":"Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib\/IIa study. JHEP Rep. 2021;3(6): 100361. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100361","journal-title":"JHEP Rep"},{"issue":"8","key":"10907_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201236","volume":"13","author":"M Al Mahtab","year":"2018","unstructured":"Al Mahtab M, Akbar SMF, Aguilar JC, et al. Treatment of chronic hepatitis B na\u00efve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial). PLoS ONE. 2018;13(8): e0201236. https:\/\/doi.org\/10.1371\/journal.pone.0201236","journal-title":"PLoS ONE"},{"key":"10907_CR5","doi-asserted-by":"publisher","first-page":"1032531","DOI":"10.3389\/fmed.2023.1032531","volume":"10","author":"M Al Mahtab","year":"2023","unstructured":"Al Mahtab M, Akbar SMF, Aguilar JC, et al. Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment. Front Med (Lausanne). 2023;10:1032531. https:\/\/doi.org\/10.3389\/fmed.2023.1032531","journal-title":"Front Med (Lausanne)"},{"issue":"35","key":"10907_CR6","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1016\/j.vaccine.2015.03.079","volume":"33","author":"J Li","year":"2015","unstructured":"Li J, Ge J, Ren S, et al. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection. Vaccine. 2015;33(35):4247\u20134254. https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.079","journal-title":"Vaccine"},{"issue":"39","key":"10907_CR7","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.1016\/j.vaccine.2014.07.027","volume":"32","author":"A Gaggar","year":"2014","unstructured":"Gaggar A, Coeshott C, Apelian D, et al. Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study. Vaccine. 2014;32(39):4925\u20134931. https:\/\/doi.org\/10.1016\/j.vaccine.2014.07.027","journal-title":"Vaccine"},{"issue":"2","key":"10907_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020184","volume":"8","author":"SK Chinnakannan","year":"2020","unstructured":"Chinnakannan SK, Cargill TN, Donnison TA, et al. The design and development of a multi-HBV antigen encoded in chimpanzee adenoviral and modified vaccinia Ankara viral vectors; a novel therapeutic vaccine strategy against HBV. Vaccines. 2020;8(2): 184. https:\/\/doi.org\/10.3390\/vaccines8020184","journal-title":"Vaccines"},{"issue":"2","key":"10907_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020330","volume":"11","author":"M Pokorska-\u015apiewak","year":"2023","unstructured":"Pokorska-\u015apiewak M, Marczy\u0144ska M. HBV and HCV infection in children and adolescents. Vaccines. 2023;11(2): 330. https:\/\/doi.org\/10.3390\/vaccines11020330","journal-title":"Vaccines"},{"issue":"36","key":"10907_CR10","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v27.i36.6053","volume":"27","author":"M Stinco","year":"2021","unstructured":"Stinco M, Rubino C, Trapani S, et al. Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol. 2021;27(36):6053\u20136063. https:\/\/doi.org\/10.3748\/wjg.v27.i36.6053","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10907_CR11","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/S2468-1253(19)30042-1","volume":"4","author":"G Indolfi","year":"2019","unstructured":"Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019;4(6):466\u2013476. https:\/\/doi.org\/10.1016\/S2468-1253(19)30042-1","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10907_CR12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","volume":"151","author":"BJ McMahon","year":"1985","unstructured":"McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985;151(4):599\u2013603. https:\/\/doi.org\/10.1093\/infdis\/151.4.599","journal-title":"J Infect Dis"},{"issue":"1","key":"10907_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1186\/s12985-024-02589-3","volume":"21","author":"Z Lei","year":"2024","unstructured":"Lei Z, Wang L, Gao H, et al. Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV. Virol J. 2024;21(1):314. https:\/\/doi.org\/10.1186\/s12985-024-02589-3","journal-title":"Virol J"},{"key":"10907_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105782","volume":"221","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Liu H, Tang L, Wang F, et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res. 2024;221: 105782. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105782","journal-title":"Antiviral Res"},{"issue":"8022","key":"10907_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/s41586-024-07630-7","volume":"631","author":"M Bosch","year":"2024","unstructured":"Bosch M, Kallin N, Donakonda S, et al. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. Nature. 2024;631(8022):867\u2013875. https:\/\/doi.org\/10.1038\/s41586-024-07630-7","journal-title":"Nature"},{"key":"10907_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cellimm.2017.07.003","volume":"321","author":"S Portugal","year":"2017","unstructured":"Portugal S, Obeng-Adjei N, Moir S, Crompton PD, Pierce SK. Atypical memory B cells in human chronic infectious diseases: an interim report. Cell Immunol. 2017;321:18\u201325. https:\/\/doi.org\/10.1016\/j.cellimm.2017.07.003","journal-title":"Cell Immunol"},{"key":"10907_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cellimm.2017.04.012","volume":"321","author":"JJ Knox","year":"2017","unstructured":"Knox JJ, Kaplan DE, Betts MR. T-bet-expressing B cells during HIV and HCV infections. Cell Immunol. 2017;321:26\u201334. https:\/\/doi.org\/10.1016\/j.cellimm.2017.04.012","journal-title":"Cell Immunol"},{"issue":"6","key":"10907_CR18","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1002\/hep.510250631","volume":"25","author":"GK Lau","year":"1997","unstructured":"Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology. 1997;25(6):1497\u20131501. https:\/\/doi.org\/10.1002\/hep.510250631","journal-title":"Hepatology"},{"issue":"3","key":"10907_CR19","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00277-009-0806-7","volume":"89","author":"SN Pei","year":"2010","unstructured":"Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255\u2013262. https:\/\/doi.org\/10.1007\/s00277-009-0806-7","journal-title":"Ann Hematol"},{"issue":"5","key":"10907_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s40880-015-0015-9","volume":"34","author":"KL Chen","year":"2015","unstructured":"Chen KL, Chen J, Rao HL, et al. Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival. Chin J Cancer. 2015;34(5):225\u2013234. https:\/\/doi.org\/10.1186\/s40880-015-0015-9","journal-title":"Chin J Cancer"},{"issue":"51","key":"10907_CR21","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1016\/j.vaccine.2007.09.072","volume":"25","author":"P Vandepapeli\u00e8re","year":"2007","unstructured":"Vandepapeli\u00e8re P, Lau GK, Leroux-Roels G, et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg\/AS02 candidate vaccine and lamivudine. Vaccine. 2007;25(51):8585\u20138597. https:\/\/doi.org\/10.1016\/j.vaccine.2007.09.072","journal-title":"Vaccine"},{"key":"10907_CR22","unstructured":"Grace LW, Apinya L, Young SL, et al. Responders to Prior BRll-179 Treatment Achieved Faster and Higher Rate of HBsAg Seroclearance Following Treatment of Elebsiran and PEG-IFN\u03b1 in Participants with Chronic Hepatitis B Virus Infection: Preliminary Data from ENSURE Study. APASL. 2025."},{"issue":"1","key":"10907_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2012.07.011","volume":"96","author":"SM Akbar","year":"2012","unstructured":"Akbar SM, Chen S, Al Mahtab M, et al. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus. Antiviral Res. 2012;96(1):59\u201364. https:\/\/doi.org\/10.1016\/j.antiviral.2012.07.011","journal-title":"Antiviral Res"},{"issue":"1\u20132","key":"10907_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1159\/000150481","volume":"39","author":"F Sch\u00f6del","year":"1996","unstructured":"Sch\u00f6del F, Peterson D, Milich D. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety. Intervirology. 1996;39(1\u20132):104\u2013110. https:\/\/doi.org\/10.1159\/000150481","journal-title":"Intervirology"},{"issue":"5","key":"10907_CR25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.3390\/vaccines11050962","volume":"11","author":"M Al Mahtab","year":"2023","unstructured":"Al Mahtab M, Akbar SMF, Yoshida O, et al. Antiviral response across genotypes after treatment of chronic hepatitis B patients with the therapeutic vaccine NASVAC or pegylated interferon. Vaccines (Basel). 2023;11(5):962. https:\/\/doi.org\/10.3390\/vaccines11050962","journal-title":"Vaccines (Basel)"},{"issue":"25","key":"10907_CR26","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.cell.2025.01.033","volume":"S0092\u20138674","author":"NA Prescott","year":"2025","unstructured":"Prescott NA, Biaco T, Mansisidor A, et al. A nucleosome switch primes hepatitis B virus infection. Cell. 2025;S0092\u20138674(25):102\u2013103. https:\/\/doi.org\/10.1016\/j.cell.2025.01.033","journal-title":"Cell"},{"issue":"3","key":"10907_CR27","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.jhep.2016.05.016","volume":"65","author":"AS Lok","year":"2016","unstructured":"Lok AS, Pan CQ, Han SH, et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65(3):509\u2013516. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.016","journal-title":"J Hepatol"},{"issue":"1","key":"10907_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.gastro.2019.03.044","volume":"157","author":"C Boni","year":"2019","unstructured":"Boni C, Janssen HLA, Rossi M, et al. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology. 2019;157(1):227\u2013241. https:\/\/doi.org\/10.1053\/j.gastro.2019.03.044","journal-title":"Gastroenterology"},{"issue":"1","key":"10907_CR29","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/S0618-8278(19)30090-8","volume":"70","author":"YS Lim","year":"2019","unstructured":"Lim YS, Mutimer D, Heo J, et al. PS-078-A phase 1b evaluation of HepTcell HBV-specific immunotherapy in nuc-controlled, eAg negative chronic HBV infection. J Hepatol. 2019;70(1):e50\u2013e51. https:\/\/doi.org\/10.1016\/S0618-8278(19)30090-8","journal-title":"J Hepatol"},{"issue":"1","key":"10907_CR30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/hep.32109","volume":"75","author":"L Wei","year":"2022","unstructured":"Wei L, Zhao T, Zhang J, et al. Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: a randomized clinical trial. Hepatology. 2022;75(1):182\u2013195. https:\/\/doi.org\/10.1002\/hep.32109","journal-title":"Hepatology"},{"key":"10907_CR31","unstructured":"ISA Pharmaceuticals. First Patient with Chronic Hepatitis B Dosed with ISA104 in First-in-Human Phase 1 Study. 2023. https:\/\/www.isa-pharma.com\/first-patient-with-chronic-hepatitis-b-dosed-with-isa104\/."},{"issue":"1","key":"10907_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41541-024-00813-3","volume":"9","author":"H Zhao","year":"2024","unstructured":"Zhao H, Shao X, Yu Y, et al. A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression. NPJ Vaccines. 2024;9(1):22. https:\/\/doi.org\/10.1038\/s41541-024-00813-3","journal-title":"NPJ Vaccines"},{"issue":"7978","key":"10907_CR33","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41586-023-06127-z","volume":"621","author":"H Zhang","year":"2023","unstructured":"Zhang H, Zhang L, Lin A, et al. Algorithm for optimized mRNA design improves stability and immunogenicity. Nature. 2023;621(7978):396\u2013403. https:\/\/doi.org\/10.1038\/s41586-023-06127-z","journal-title":"Nature"},{"key":"10907_CR34","unstructured":"Jiyan Liu. A Trial to Evaluate the Efficacy and Safety of WGc0201 in Patients With Chronic Hepatitis B Virus Infection (WGc0201-HBV). 2025. https:\/\/clinicaltrials.gov\/study\/NCT07051187?cond=NCT07051187&rank=1."},{"issue":"1","key":"10907_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/gutjnl-2013-305707","volume":"64","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Kahi S, Chazallon C, et al. Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial\u2013ANRS HB02 VAC-AND. Gut. 2015;64(1):139\u2013147. https:\/\/doi.org\/10.1136\/gutjnl-2013-305707","journal-title":"Gut"},{"issue":"6","key":"10907_CR36","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3321\/j.issn:0577-7402.2003.06.007","volume":"28","author":"X He","year":"2003","unstructured":"He X, Chen X, Huang Y, et al. Construction and identification of therapeutic double-plasmid HBV DNA vaccine. PLA medical journal. 2003;28(6):5. https:\/\/doi.org\/10.3321\/j.issn:0577-7402.2003.06.007","journal-title":"PLA medical journal"},{"issue":"2","key":"10907_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3748\/wjg.v23.i2.306","volume":"23","author":"FQ Yang","year":"2017","unstructured":"Yang FQ, Rao GR, Wang GQ, et al. Phase IIb trial of in vivo electroporation mediated dual-plasmid hepatitis B virus DNA vaccine in chronic hepatitis B patients under lamivudine therapy. World J Gastroenterol. 2017;23(2):306\u2013317. https:\/\/doi.org\/10.3748\/wjg.v23.i2.306","journal-title":"World J Gastroenterol"},{"key":"10907_CR38","unstructured":"Guangzhou Baiyunshan Pharmaceutical Group Co., LTD. Acquisition of a Phase IIc clinical study report on Therapeutic double plasmid HBV DNA vaccine. 2023 http:\/\/static.sse.com.cn\/disclosure\/listedinfo\/announcement\/c\/new\/2023\u201306\u201302\/600332_20230602_82SR.pdf."},{"issue":"6","key":"10907_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3858\/emm.2008.40.6.669","volume":"40","author":"CY Kim","year":"2008","unstructured":"Kim CY, Kang ES, Kim SB, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med. 2008;40(6):669\u2013676. https:\/\/doi.org\/10.3858\/emm.2008.40.6.669","journal-title":"Exp Mol Med"},{"issue":"3","key":"10907_CR40","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/liv.12530","volume":"35","author":"SK Yoon","year":"2015","unstructured":"Yoon SK, Seo YB, Im SJ, et al. Safety and immunogenicity of therapeutic DNA vaccine with antiviral drug in chronic HBV patients and its immunogenicity in mice. Liver Int. 2015;35(3):805\u2013815. https:\/\/doi.org\/10.1111\/liv.12530","journal-title":"Liver Int"},{"issue":"11","key":"10907_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100885","volume":"5","author":"T Cargill","year":"2023","unstructured":"Cargill T, Cicconi P, Brown A, et al. HBV001: phase i study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV. JHEP Reports. 2023;5(11): 100885. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100885","journal-title":"JHEP Reports"},{"issue":"4","key":"10907_CR42","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1093\/infdis\/jiad340","volume":"229","author":"S Schmidt","year":"2024","unstructured":"Schmidt S, Mengistu M, Daffis S, et al. Alternating arenavirus vector immunization generates robust polyfunctional genotype cross-reactive hepatitis B virus-specific CD8 T-cell responses and high anti-hepatitis B surface antigen titers. J Infect Dis. 2024;229(4):1077\u20131087. https:\/\/doi.org\/10.1093\/infdis\/jiad340","journal-title":"J Infect Dis"},{"key":"10907_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","volume":"11","author":"H Lauterbach","year":"2021","unstructured":"Lauterbach H, Schmidt S, Katchar K, et al. Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform. Front Oncol. 2021;11: 732166. https:\/\/doi.org\/10.3389\/fonc.2021.732166","journal-title":"Front Oncol"},{"issue":"1","key":"10907_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jhep.2023.09.019","volume":"80","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Bourgine M, Wan Y, et al. Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers. J Hepatol. 2024;80(1):31\u201340. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.019","journal-title":"J Hepatol"},{"key":"10907_CR45","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.immunol.19.1.65","volume":"19","author":"LG Guidotti","year":"2001","unstructured":"Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol. 2001;19:65\u201391. https:\/\/doi.org\/10.1146\/annurev.immunol.19.1.65","journal-title":"Annu Rev Immunol"},{"key":"10907_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.779347","volume":"12","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Lu J, et al. Pegylated interferon treatment for the effective clearance of hepatitis B surface antigen in inactive HBsAg carriers: a meta-analysis. Front Immunol. 2021;12: 779347. https:\/\/doi.org\/10.3389\/fimmu.2021.779347","journal-title":"Front Immunol"},{"issue":"4","key":"10907_CR47","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66(4):1058\u20131066. https:\/\/doi.org\/10.1002\/hep.29213","journal-title":"Hepatology"},{"key":"10907_CR48","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.3389\/fimmu.2018.01561","volume":"9","author":"SF Lumley","year":"2018","unstructured":"Lumley SF, McNaughton AL, Klenerman P, et al. Hepatitis B virus adaptation to the CD8+ T cell response: consequences for host and pathogen. Front Immunol. 2018;9:1561. https:\/\/doi.org\/10.3389\/fimmu.2018.01561","journal-title":"Front Immunol"},{"issue":"4","key":"10907_CR49","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3350\/cmh.2024.0058","volume":"30","author":"X Wan","year":"2024","unstructured":"Wan X, Wisskirchen K, Jin T, et al. Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting. Clin Mol Hepatol. 2024;30(4):735\u2013755. https:\/\/doi.org\/10.3350\/cmh.2024.0058","journal-title":"Clin Mol Hepatol"},{"key":"10907_CR50","doi-asserted-by":"crossref","unstructured":"Zhang Q, Fu Q, Cao W, et al. First report of preliminary safety, efficacy, and pharmacokinetics of C-CAR031 (GPC3-specific TGF\u03b2RIIDN CAR-T) in patients with advanced HCC. AACR 2023.","DOI":"10.1158\/1538-7445.AM2023-CT097"},{"key":"10907_CR51","unstructured":"OriginCell Therapeutics (Shanghai) Co., Ltd. An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial. ASCO 2021. https:\/\/meetinglibrary.asco.org\/record\/199036\/abstract."}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10907-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-025-10907-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-025-10907-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:20:14Z","timestamp":1766078414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-025-10907-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10907"],"URL":"https:\/\/doi.org\/10.1007\/s12072-025-10907-2","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,27]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that there are no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}